Menu
No results found.
Weekly Share Price & Valuation Overview
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.
- ROE ≥15% reflects strong returns on shareholder equity.
- Quick ratio <0.8 — tight near-term liquidity without inventory.
- Debt-to-equity >2 — elevated leverage may constrain flexibility.
- Debt/EBITDA >4 — elevated leverage vs earnings capacity.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 32.49B
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 46.05B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 15.70B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 5.38B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD 2.92B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 88.62
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 6.90
- Shares Outstanding
- 170.00M
- Float Shares
- 161.43M
- Implied Shares Outstanding
- 176.17M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
13.39%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
18.62%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
34.25%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
7.88%
- ROA Return on assets: net income ÷ total assets.
-
5.16%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
19.79%
- Revenue Growth Year-over-year revenue growth.
-
5.30%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-21.80%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-26.70%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.74
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 2.72
- Total Cash Cash and equivalents.
- USD 2.19B
- Total Debt Short + long-term interest-bearing debt.
- USD 15.75B
- Net Debt Total debt − cash (negative = net cash).
- USD 13.56B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 5.39
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD 2.62B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD 2.45B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
16.67%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
15.62%
- Cash Conversion (OpCF/EBITDA)
- 0.90
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.